Researchers found that an inhaled drug called LAM-001 may significantly improve lung function in people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). In a recent study, patients experienced a notable increase in their six-minute walk distance (6MWD) by an average of 67.4 meters and a reduction in pulmonary vascular resistance (PVR) by 33.9% over 24 weeks. These improvements suggest that LAM-001 could enhance exercise capacity and overall lung health for those struggling with this debilitating condition.

This discovery is particularly important for individuals with PH-ILD, a serious condition affecting around 86,000 people in the U.S. alone. Many of these patients face daily challenges due to limited lung function and ongoing symptoms despite existing treatments. The improvements seen in the study could mean better quality of life, greater mobility, and reduced strain on the heart for those affected. Transitioning from a more severe functional class to a less severe one indicates a meaningful shift towards improved health.

The evidence comes from a Phase 2a study involving 10 adults with PAH and PH-ILD, where LAM-001 was tested alongside standard care. While the results are promising, they are still in the early stages of research. A larger Phase 2b trial is set to begin in mid-2026, with results expected in early 2028. This means that while the findings are encouraging, more extensive testing is needed to confirm the drug’s effectiveness and safety in a broader population.

For now, those interested in improving lung health should stay informed about upcoming studies and potential treatments like LAM-001. Engaging with healthcare providers about new therapies may provide options for better management of pulmonary conditions.

Source: globenewswire.com